Figures & data
Table 1. Baseline demographic characteristics.
Table 2. Baseline clinical characteristics.
Figure 1. Treatment duration for vemurafenib, dacarbazine, and temozolomide.
Figure 2. Treatment course for ipilimumab (N = 405).
- Choose new content alerts to be informed about new research of interest to you
- Easy remote access to your institution's subscriptions on any device, from any location
- Save your searches and schedule alerts to send you new results
- Export your search results into a .csv file to support your research